Recent Updates
Recently added Catalysts

Adjuvanted herpes simplex candidate vaccine GSK 208141

Phase 1

Prophylaxis Herpes Simplex | Vaccine | Infectious Disease |GSK plc|Trials Updated: Jun 17, 2008

Adjuvanted herpes simplex candidate vaccine GSK 208141 target and mechanism

ModalityVaccine

Also known as Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment130

FDA Designations

No designations recorded

Adjuvanted herpes simplex candidate vaccine GSK 208141 clinical trials

Adjuvanted herpes simplex candidate vaccine GSK 208141 · 1 trial · 1 indication

Phase 1 1
NCT00698490Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell LinesProphylaxis Herpes Simplex
COMPLETED130 Analytics
PHASE1COMPLETED
Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines
Prophylaxis Herpes Simplex
NCT00698490130
Unlock trial analytics

Study Endpoints

Primary Endpoints

To evaluate in initially HSV-seronegative subjects the GMT's and the seroconversion rates of anti-gD2 antibodies (ELISA)
After the second and third doses of each vaccine
To evaluate in initially HSV-seronegative subjects, the GMT and the seropositivity rate of anti-HSV-2 neutralizing antibodies
To evaluate the cell-mediated immune (CMI) response (lymphoproliferation, secretion of interleukin 2 and γ interferon)
After the second and third dose of each vaccine formulation
To evaluate, in initially seronegative subjects and in initially seropositive subjects, the incidence and intensity of solicited local and general signs and symptoms
During 3 days after each dose of each vaccine
To evaluate in initially seropositive subjects, the GMT and the seropositivity rate of anti-gD2 antibodies (ELISA) and of anti-HSV-2 neutralizing antibodies
After 2 and 3 doses of vaccines
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
Group AEXPERIMENTALHSV-seronegative subjects
Group BEXPERIMENTALHSV-seropositive subjects
Group CEXPERIMENTALHSV-seronegative subjects
Group DEXPERIMENTALHSV-seronegative subjects
Group EEXPERIMENTALHSV-seronegative subjects

Interventions

NameTypeDescription
Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141BIOLOGICALIntramuscular injection, 3 doses, 2 different formulations
Herpes simplex virus containing gD-AlumBIOLOGICALIntramuscular injection, 3 doses
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 45 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Between 18 and 45 years of age * Written informed consent * Female volunteers must be using contraception and should avoid becoming pregnant for the duration of the vaccination course * Serology: Groups 1, 3, 4 and 5: HSV-1 AND HSV-2 seronegative (by gD2 ELISA); Group 2: HSV s...

Countries:Belgium
Unlock Eligibility Criteria

Frequently asked questions about Adjuvanted herpes simplex candidate vaccine GSK 208141

What is Adjuvanted herpes simplex candidate vaccine GSK 208141?

Adjuvanted herpes simplex candidate vaccine GSK 208141 is an investigational vaccine developed by GSK plc for prophylaxis of herpes simplex. It is designed to prevent herpes simplex infection and is in Phase 1 clinical development. The vaccine is also known as the adjuvanted herpes simplex (gD) candidate vaccine GSK 208141.

What is Adjuvanted herpes simplex candidate vaccine GSK 208141 used for?

Adjuvanted herpes simplex candidate vaccine GSK 208141 is being developed for prophylaxis of herpes simplex, meaning it is intended to prevent herpes simplex infection. It is an investigational vaccine and has not been approved for any indication.

Who makes Adjuvanted herpes simplex candidate vaccine GSK 208141?

Adjuvanted herpes simplex candidate vaccine GSK 208141 is developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor of the clinical program for this investigational vaccine.

What phase is Adjuvanted herpes simplex candidate vaccine GSK 208141 in?

Adjuvanted herpes simplex candidate vaccine GSK 208141 is in Phase 1 clinical development. It is an investigational vaccine and has not been approved by the FDA or any regulatory agency. The Phase 1 trial has been completed.

What clinical trials is Adjuvanted herpes simplex candidate vaccine GSK 208141 in?

Adjuvanted herpes simplex candidate vaccine GSK 208141 has been studied in one completed Phase 1 trial, NCT00698490, titled Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines. The trial enrolled 130 healthy volunteers in Belgium and was randomized and controlled.

Explore more on BiopharmaWatch

GSK plc (GSK)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with ACompanies A to ZEvery biotech and pharma company we track